This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Oct 14;351(16):1690-1; author reply 1690-1.

Bevacizumab in colorectal cancer

Waseem Sharieff

PMID: 15490497

Comment

Bevacizumab in colorectal cancer

Waseem Sharieff. N Engl J Med. 2004.

. 2004 Oct 14;351(16):1690-1; author reply 1690-1.

Author

Waseem Sharieff

PMID: 15490497

No abstract available

PubMed Disclaimer

Comment on

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Clinical Trial.

Similar articles

Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Boisen MK, Johansen JS, Larsen O, Jensen BV. Boisen MK, et al. Oncology. 2011;80(1-2):138-9. doi: 10.1159/000327237. Epub 2011 Jun 15. Oncology. 2011. PMID: 21677460 No abstract available.
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Kabbinavar F, Kozloff M. Kabbinavar F, et al. Oncology. 2011;80(1-2):135-7; author reply 140-1. doi: 10.1159/000327227. Epub 2011 Jun 15. Oncology. 2011. PMID: 21677459 No abstract available.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Hurwitz H, et al. N Engl J Med. 2004 Jun 3;350(23):2335-42. doi: 10.1056/NEJMoa032691. N Engl J Med. 2004. PMID: 15175435 Clinical Trial.
Common side effects and interactions of colorectal cancer therapeutic agents.
Holt K. Holt K. J Pract Nurs. 2011 Spring;61(1):7-20. J Pract Nurs. 2011. PMID: 21751717 Review. No abstract available.
[Progress of chemotherapy in colorectal cancer].
Komatsu Y. Komatsu Y. Gan To Kagaku Ryoho. 2007 Nov;34(11):1771-6. Gan To Kagaku Ryoho. 2007. PMID: 18064761 Review. Japanese. No abstract available.

See all similar articles

Cited by

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.
Yang Y, Zhang Y, Cao Z, Ji H, Yang X, Iwamoto H, Wahlberg E, Länne T, Sun B, Cao Y. Yang Y, et al. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12018-23. doi: 10.1073/pnas.1301331110. Epub 2013 Jul 1. Proc Natl Acad Sci U S A. 2013. PMID: 23818623 Free PMC article.
Non-angiogenic functions of VEGF in breast cancer.
Mercurio AM, Lipscomb EA, Bachelder RE. Mercurio AM, et al. J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):283-90. doi: 10.1007/s10911-006-9001-9. J Mammary Gland Biol Neoplasia. 2005. PMID: 16924371 Review.
The extracellular matrix glycoprotein elastin microfibril interface located protein 2: a dual role in the tumor microenvironment.
Mongiat M, Marastoni S, Ligresti G, Lorenzon E, Schiappacassi M, Perris R, Frustaci S, Colombatti A. Mongiat M, et al. Neoplasia. 2010 Apr;12(4):294-304. doi: 10.1593/neo.91930. Neoplasia. 2010. PMID: 20360940 Free PMC article.
Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model.
Qiao T, Zhao J, Xin X, Xiong Y, Guo W, Meng F, Li H, Feng Y, Xu H, Shi C, Han Y. Qiao T, et al. Cancer Immunol Immunother. 2023 May;72(5):1169-1181. doi: 10.1007/s00262-022-03318-x. Epub 2022 Nov 10. Cancer Immunol Immunother. 2023. PMID: 36357599 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information